Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib and Fruquintinib with Tislelizumab for Solid Tumors

 Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib and Fruquintinib with Tislelizumab for Solid Tumors

Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib and Fruquintinib with Tislelizumab for Solid Tumors

Shots:

  • The two companies collaborated to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib and fruquintinib, with BeiGene’s tislelizumab against multiple solid tumor cancer indications in the US, EU, China and Australia. Both the companies will mutually supply drug and other support
  • Tislelizumab is an anti PD-1 mAb, specifically designed to minimize binding to FcγR, which is believed to play an essential role in activating phagocytosis in macrophages, to minimize its negative impact on T effector cells while fruquintinib improves kinase selectivity against VGEFR to minimize off-target toxicities
  • Surufatinib is a VEGFR inhibitor, inhibits CSF-1R, blocks the accumulation of tumor-associated macrophages and promoting infiltration of T effector cells into tumors, leading to possible synergistic anti-tumor activity with PD-1 inhibitors

Click here to­ read full press release/ article | Ref: Business wire | Image: BeiGene

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post